Top Markets
#1 Black Phoenix Black Phoenix +357.53%
#2 Islamic Coin Islamic Coin +158.14%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +19.93%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#6 Victoria VR Victoria VR +7.35%
#7 Pons Pons +6.63%
#8 COTI COTI +6.01%
#9 Movement Movement +5.28%
#10 Palladium Network Palladium Network +5.16%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc.

TMBR
Classement en actions #42059
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.
Prix de l'action
$0.0101
Dernière synchronisation: 2023-12-26
Capitalisation boursière
$5.32K
Changement (1 jour)
741.67%
Changement (1 an)
0.00%
Pays
US
Échange Timber Pharmaceuticals, Inc. (TMBR)

Catégorie

Healthcare
Bénéfices pour Timber Pharmaceuticals, Inc. (TMBR)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Timber Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Timber Pharmaceuticals, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE